KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2025)

Amneal Pharmaceuticals has reported Share-based Compensation over the past 8 years, most recently at $8.2 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $8.2 million for Q4 2025, up 13.76% from a year ago — trailing twelve months through Dec 2025 was $32.0 million (up 15.07% YoY), and the annual figure for FY2025 was $32.0 million, up 15.07%.
  • Share-based Compensation for Q4 2025 was $8.2 million at Amneal Pharmaceuticals, roughly flat from $8.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for AMRX hit a ceiling of $8.3 million in Q2 2025 and a floor of $5.3 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $7.6 million (2021), compared with a mean of $7.3 million.
  • Biggest five-year swings in Share-based Compensation: surged 51.31% in 2022 and later fell 23.71% in 2023.
  • Amneal Pharmaceuticals' Share-based Compensation stood at $7.7 million in 2021, then increased by 1.15% to $7.8 million in 2022, then fell by 23.71% to $6.0 million in 2023, then grew by 20.69% to $7.2 million in 2024, then rose by 13.76% to $8.2 million in 2025.
  • The last three reported values for Share-based Compensation were $8.2 million (Q4 2025), $8.2 million (Q3 2025), and $8.3 million (Q2 2025) per Business Quant data.